IMID Patients

Immune-mediated inflammatory diseases are a group of chronic disorders characterized by activation of multiple immune and inflammatory pathways. While each IMID involves different tissues and organs, they share many common features and molecular mechanisms. While their cause is unknown, genetic and environmental factors are known to increase risk levels for IMIDs. Nearly 10% of all people are living with an IMID. In many cases, IMIDs bear a heavy socio-economic costs and in many developed nations are among the main causes of morbidity, disability, and mortality

The IMID pathologies investigated by IMIDomics include:


IMIDomics has access to large cross-sectional and longitudinal cohorts of IMID patients:


The common goals for all IMID treatments are controlling local and systemic inflammation, establishing long-duration remission, preventing and repairing tissue damage and improving quality of life for patients. Too often, existing medications do not meet these goals because of lack of response, prevalence of serious side effects of the development of resistance

IMIDomics’ Precision Discovery Platform is designed to create a deeper understanding of IMID patients and their diseases to discover and develop new, more effective medications

IMID Biobank

IMIDomics and VHIR partnered to grow the IMID Biobank, providing IMIDomics with exclusive commercial access to its data and samples. The IMID Biobank is an ISO9001-certified reference public resource, led and operated by the Vall d’Hebron University Hospital which manages collection, processing, storage and systems for sample access

The Biobank promotes cutting-edge research on IMIDs to improve patient care and treatment outcomes. The Biobank contains and continues to collect cross-sectional and longitudinal patient samples across the following indications:

  • Rheumatoid Arthritis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Psoriasis
  • Psoriatic Arthritis
  • Systemic Lupus Erythematosus
  • Atopic Dermatitis
  • Sjogren’s Syndrome
  • Hypernormal Control Subjects

The Biobank also contains both cross-sectional and longitudinal samples. Collection protocols remain open and collections continue to expand the Biobank on a daily basis

IMIDomics has access to large cross-sectional and longitudinal cohorts of IMID patients:


The IMID-Biobank created in 2007 is located in the Barcelona Science Park and operates according to the current Spanish and European legislation on biomedical research and data protection

Multiomics

At IMIDomics, we know that the only way to discover therapeutically relevant treatments for IMIDs is through a multiomic approach that fully integrates clinical, real-world and disease mechanistic data. This is because IMIDs are complex diseases, involving many immune mechanisms. Some are shared across indications while others are unique to specific disorders. As a result, some patients may appear similar but respond differently to medication, while others present differently but share certain common disease mechanisms

IMIDomics’s Precision Discovery Platform allows us to properly characterize patients and direct drug discovery toward treatment of specific patient cohorts, thereby enabling precision medicines

IMIDomics’ Precision Discovery Platform uses multiple cutting-edge technologies to interrogate different layers of biological information:


From the inherited DNA variation to the heterogeneous clinical manifestations of IMIDs, there are many aspects of biological variability that can now be interrogated with the use of biomolecular and digital technologies

Our long-standing collaboration with the HudsonAlpha Institute for Biotechnology has accelerated our ability to extract the highest quality biomolecular data form IMID Biobank patient samples. IMIDomics has also partnered with other bioanalytical experts to build our biomolecular data using the most up-to-date technologies

Portal

At IMIDomics, we have developed and are implementing a proprietary digital Portal that integrates real-world, clinical and molecular data from IMID patients at an unprecedented quality, depth and scale

Through the Portal, we can access unique and essential insights that power our Precision Discovery Platform. Researchers can get a granular view of a patient’s condition, test hypotheses, and compare against biomolecular, clinical and/or real-world feature. Using state-of-the-art analytics and machine learning we continually improve the Portal as new patients, data types and analytical methods become available

Case study

Our Precision Discovery Platform has discovered 5 distinct classes of SLE patients. IMIDomics’s Portal analysis of phenotypic and molecular data of patients with systemic lupus erythematosus (SLE) yielded groups of patients with distinct clinical features

  • High quality transcriptome profiling (RNA-Seq) in a large cohort of SLE patients identifies distinct and reproducible biological classes
  • New molecular classes have the power to improve treatment efficacy in SLE and develop new indications for existing drugs

SLE Class 1

Responsive to JAK inhibitors

SLE Class 2

Higher risk for renal affection

SLE Class 3

Responsive to anti-CD20

SLE Class 4

New Drug Target Class

SLE Class 5

High risk for arthritis